Русский
Experience of treatment with direct-acting antiviral drugs in patients with cirrhosis at the outcome of chronic hepatitis
Khaertynova I.M., Sozinova Yu.M., Galeeva N.V., Gaifullina E.G., Urmancheeva Yu.R., Gataullin M.R.
1Kazan State Medical Academy, Branch, Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia, Kazan, Russia; 2Prof. A.F. Agafonov Republican Clinical Infectious Diseases Hospital, Kazan, Russia
Subjects and methods. The study included 12 patients with classes A and B cirrhosis who had previously untreated or failed to respond to therapy with IFN-containing regimens. All the patients received paritaprevir/ritonavir/ombitasvir (75/50/12.5 mg) 2 tablets once daily and dasabuvir (250 mg) 1 tablet twice daily for 12 weeks.
Results. All the 12 patients completed a full therapy cycle. A sustained virologic response was obtained in all the patients at 12 and 24 weeks after treatment completion. The most common adverse events were weakness (33%) and headache (33%).
Conclusion. The results of therapy with paritaprevir/ritonavir/ombitasvir and dasabuvir allow it to be regarded as highly effective and safe for patients with HCV-related cirrhosis.
Literature
1. Guidelines for the screening, care and treatment of persons with hepatitis C infections. http://www.who.int/hiv/pub/hepatitis/ hepatitis-c- guidelines/en/ 2. Pimenov N.N., Vdovin A.V., Komarova S.V., Mamonova N.A., Chulanov V.P., Pokrovskij V.I. [The relevance and prospects of introducing a uniform federal register of patients with viral hepatitis B and C in Russia]. Terapevticheskij Arhiv 2013; (11): 4–9. (In Russ.). 3. Brown R.S. Jr. Hepatitis C and liver transplantation. Nature 2005; 436(7053): 973–8. 4. Muhlberger N., Schwarzer R., Lettmeier B., Sroczynski G., Zeuzem S., Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009; (9): 34. 5. Tholey D.M., Ahn J. Impact of hepatitis C Virus Infection on Hepatocellular Carcinoma. Gastroenterol. Clin. North Am. 2015; 44(4): 761–73. 6. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: 237–44. 7. Bakulin I.G., Sandler Yu.G. [Liver сirrhosis: what”s new in treatment]. Еffektivnaya Farmakoterapiya 2014; 43: 42–50. (In Russ.). 8. Burnevich Ye.Z., Shhanicyna S.E. [Antiviral therapy of chronic hepatitis C, based on interferon-α: patterns and principles]. Klinicheskaya Farmakologiya i Terapiya 2016; (1): 8–13. (InRuss.). 9. Smith-Palmer J., Cerri K., Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect. Dis. 2015; 15(19): 2013–19. 10. Forns X., Navasa M., Rodes J. Treatment of HCV infection in patients with advanced cirrhosis. Hepatology 2004; 40: 498. 11. Iacobellis A., Ippolito A., Andriulli A. Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. World J. Gastroenterol. 2008; 14(42): 6467–72. 12. Iacobellis A., Andriulli A. Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection. Expert Opin. Pharmacother. 2009; (10): 1929–38. 13. Poordad F., Hezode C., Trinh R., Kowdley K.V., Zeuze m S., Agarwal K., Shiffman M.L., Wedemeyer H., Berg T., Yoshida E.M., Forns X., Lovell S.S., Da SilvaTillmann B., Collins C.A., Campbell A.L., Podsadecki T., Bernstein B. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N. Engl. J Med. 2014; 370: 1973–82. 14. Feld J.J., Moreno C., Trinh R., Tam E., Bourgeois S., Horsmans Y., Elkhashab M., Bernstein D.E., Younes Z., Reindollar R.W., Larsen L., Fu B., Howieson K., Polepally A.R., Pangerl A., Shulman N.S., Poordad F. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. Hepatology 2016; 64(2): 301–7.
About the Autors
For сorrespondence: Elza G. Gaifullina, e-mail: elsagaj@yandex.ru
Similar Articles
